Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.

ABSTRACT:

Objective

To analyze longitudinal levels of CSF biomarkers in drug-naive patients with Parkinson disease (PD) and healthy controls (HC), examine the extent to which these biomarker changes relate to clinical measures of PD, and identify what may influence them.

Methods

CSF α-synuclein (α-syn), total and phosphorylated tau (t- and p-tau), and β-amyloid 1-42 (Aβ42) were measured at baseline and 6 and 12 months in 173 patients with PD and 112 matched HC in the international multicenter Parkinson's Progression Marker Initiative. Baseline clinical and demographic variables, PD medications, neuroimaging, and genetic variables were evaluated as potential predictors of CSF biomarker changes.

Results

CSF biomarkers were stable over 6 and 12 months, and there was a small but si

SUBMITTER: Mollenhauer B 

PROVIDER: S-EPMC5679418 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature